ImetelChat

Very interesting! There are some changes to the protocol of IMerge. They skipped the following sentence completely: "../.. in transfusion-dependent participants with low or intermediate-1 risk MDS that is relapsed/refractory to ESA treatment.". The following sentence has been removed too: "phase (un...

Thanks, Phil. I shows that imetelstat is not out of sight for NSCLC. This study clearly has an open end. After approval we will probably see that old trials and studies are being picked up again, such as the NSCLC, MM and Pancreatic.

EMA’s PRIME can help speed delivery of new medicines to patients – by Susan Forda (1st March 2016) Last week, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted the Priority Medicines (PRIME) scheme. PRIME is a welcome step towards connecting healthcare dec...

Thanks, bio. Is changed now.

Telomerase in hematologic malignancies. C. Bruedigam, S.W. Lane Abstract PURPOSE OF REVIEW: The activation of telomere maintenance pathways has long been regarded as a key hallmark of cancer and this has propelled the development of novel inhibitors of telomerase. In this review, we detail the backg...

From the report: New surprises from an old favourite: The emergence of telomerase as a key player in the regulation of cancer stemness K. Teralı, A. Yilmazer (2015) Highlights • Telomerase has the capacity to regulate numerous cancer-promoting genes and pathways. • A mechanistic explanation for the ...

It depends when they are starting/have started to make profit. But even then they can carryforward their losses to reduce taxes on their own revenues, until off course the years of losses have been slipped away beyond the 7 years.

Hi Bio, this is from Investopedia: 'Loss Carryforward': "An accounting technique that applies the current year's net operating losses to future years' profits in order to reduce tax liability. Generally accepted accounting principles (GAAP) specify that loss carryforwards can be used in any one of t...

Nice video report about imetelstat from ASH2015 by Dr. Aaron Gerds on OncologyTube.com: Description: Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses Imetelstat Pilot Study Data Released for MPN Patients Link: http://www.oncologytube.co...

Interesting post, Jayfish. For me it doens't look scary as it is a drug that stimulates the production of blood cells. It doesn't look like a silver bullet as the compound doesn't seem to target the underlying disease. Although the Mayo study (see below) didn't observe changes on the mutations, imet...

Nice, balanced article by Zach Hartman, PhD (SA, June 1, 2016). Some quotes: ========== ../.. GERN focused its efforts on promising clinical programs in myelodysplastic syndromes. This is where the rubber hit the road for GERN. In 2014, the company partnered with J&J (NYSE:JNJ), which provided an in...

So the Geron website is updated after all! Here is the link:

http://phx.corporate-ir.net/External.Fi ... 02MzY3Mzk=

(also on imetelstat.info under 'clinical' tab)

Taken from Mesa's Twitter Blog:

https://pbs.twimg.com/media/CkRUFaqWgAEAc_B.jpg

From the photo:

Status:
- Approximately 97 sites are planned in 12 countries
- Enrollment began in June 2015 and is ongoing
- As of May 25, 2016, there are 77 active sites

Maybe they believe imetelstat/telomrease inhibition is a relevant topic?

Wasn't there some new legislation in the US on compassionate use?

Look at it from the bright side: due to the hold the FDA had the opportunity to take a close look at safety. And they lifted the hold completely. How big is the chance we'll get another one? Not so big I'd guess. That means a lowered risk for the approval path.

You're right, Bio. It is part of the communication path and will also be supporitve for the enrolment of patients for the clinical trials. For me that's important enough, certainly with an authorblock of 18 great specialists and JnJ as co-author.... This is what I posted on 19 April about my expecta...

Bio, agreed regarding the negative impact of the hold for patients. But I can't completely follow your third comment regarding JnJ. As far as I know JnJ was already talking with Geron way before the hold was installed. So it seems likely that Geron would have signed up with JnJ anyway, also if the h...

Hi Hunt, thanks for this very touching story....Life certainly is not a dressed rehearsal. Sometimes people first need to get very sick before this is well understood. I feel with you and your sister. Let's hope that access to imetelstat will getting more easy as soon as possible for those who still...

Secrecy is a difficult thing. For the business it is a prerequisite. For patients it can be misleading. For shareholders too. We can just hope that the investigators of new drugs are keeping their integrity. I put a lot of trust in Tefferi, Mesa, Verstovsek, Vannucchi, Kiladjian, Silver, Hoffman, Ce...